Case Report
J Rheum Dis 2012; 19(5): 280-284
Published online October 30, 2012
© Korean College of Rheumatology
TNF-Ձ 억제제로 치료중인 연소성 류마티스관절염 환자에게서 발생한 2차성 아밀로이드증
민홍기ㆍ윤문희ㆍ김은오ㆍ김대원ㆍ김남용ㆍ곽승기ㆍ박성환ㆍ김호연ㆍ주지현
가톨릭대학교 의과대학 서울성모병원 류마티스내과
Secondary Amyloidosis Development in a Patient with Juvenile Rheumatoid Arthritis on TNF-Ձ Inhibitors Treatment
Correspondence to : Ji Hyeon Ju
Secondary amyloidosis is one of the most serious complications in chronic inflammatory diseases such as rheumatoid arthritis. The extracellular deposit of aggregates of amyloid leads to target organ dysfunction. The mainstay treatment of secondary amyloidosis is the control of underlying disease activity. Many reports have reported that TNF-Ձ inhibitors improve clinical outcomes. Here, we encountered a 34-year-old patient with juvenile rheumatoid arthritis who developed secondary amyloidosis despite treatment with TNF-Ձ inhibitors. We present this case and include a review of the literature.
Keywords TNF-Ձ inhibitor, Rheumatoid arthritis, Amyloidosis
PDF
Standard view
Export citation
Share Article
Case Report
J Rheum Dis 2012; 19(5): 280-284
Published online October 30, 2012
Copyright © Korean College of Rheumatology.
TNF-Ձ 억제제로 치료중인 연소성 류마티스관절염 환자에게서 발생한 2차성 아밀로이드증
민홍기ㆍ윤문희ㆍ김은오ㆍ김대원ㆍ김남용ㆍ곽승기ㆍ박성환ㆍ김호연ㆍ주지현
가톨릭대학교 의과대학 서울성모병원 류마티스내과
Secondary Amyloidosis Development in a Patient with Juvenile Rheumatoid Arthritis on TNF-Ձ Inhibitors Treatment
Hong Ki Min, Moon-Hee Yoon, Eun-Oh Kim, Dae-Won Kim, Nam-Yong Kim, Seung-Ki Kwok, Sung-Hwan Park, Ho-Youn Kim, Ji Hyeon Ju
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Correspondence to:Ji Hyeon Ju
Abstract
Secondary amyloidosis is one of the most serious complications in chronic inflammatory diseases such as rheumatoid arthritis. The extracellular deposit of aggregates of amyloid leads to target organ dysfunction. The mainstay treatment of secondary amyloidosis is the control of underlying disease activity. Many reports have reported that TNF-Ձ inhibitors improve clinical outcomes. Here, we encountered a 34-year-old patient with juvenile rheumatoid arthritis who developed secondary amyloidosis despite treatment with TNF-Ձ inhibitors. We present this case and include a review of the literature.
Keywords: TNF-Ձ, inhibitor, Rheumatoid arthritis, Amyloidosis
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Rituximab for Rheumatoid Arthritis Following TNF-Ձ Inhibitor Associated Splenic Tuberculosis
Jin Su Kim, Jung Ran Choi, Jung-Soo Song, Kyung Joon Kim, Youn Su Park, Jun Hwan Cho, Min Jee Han, Sang Tae Choi
J Rheum Dis 2013; 20(2): 108-112 -
Rheumatoid Arthritis with Secondary Amyloidosis and Chronic Kidney Disease with a Good Response to Etanercept
Hyun Woo Kim, Jung Won Noh, Jinseok Kim
J Rheum Dis 2013; 20(6): 389-392 -
A Case of Psoriasiform Dermatitis Followed by Tumor Necrosis Factor Inhibitor Treated with Phototherapy
Gyun Seop Lim, Hyung Nam Kim, Bo-Bae Kim1, Dong Hyun Kim, Yun Sung Kim, Hyun-Sook Kim
J Rheum Dis 2013; 20(4): 270-274
